Headquartered in South San Francisco, CA Fiscal year ends December NASDAQ: LYEL lyell.com
Lyell Immunopharma is a late-stage clinical biotechnology company developing next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with hematologic malignancies and solid tumors. The company's technology platform employs a suite of enhancements to arm CAR T cells with improved durability, stemness, and the ability to function in hostile tumor microenvironments. Its lead product candidate, rondecabtagene autoleucel (ronde-cel), is a dual-targeting CD19/CD20 CAR T-cell therapy in pivotal trials for relapsed/refractory large B-cell lymphoma in both third-line-plus and second-line settings, with FDA RMAT, Fast Track, and Orphan Drug designations. Its second key candidate, LYL273, targets guanylyl cyclase C (GCC) for metastatic colorectal cancer and other GCC-expressing solid tumors, currently in Phase 1/2 development in the U.S. The company operates its own manufacturing facility, LyFE, with expected capacity to produce more than 1,200 CAR T-cell doses per year to support potential commercial launch. Lyell trades on Nasdaq under the ticker LYEL. Updated
Wall Street analysts made some dramatic moves on Thursday, slashing price targets by double digits on several high-profile names while upgrading others to buy. Find out which stocks got the most surprising…
Are you interested in investing in penny stocks? Though doing so does come with risk, making the right investment decisions in the penny stock category can produce eye-opening returns. While the profits…
Lyell Immunopharma is a late-stage clinical biotechnology company developing next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with hematologic malignancies and solid tumors.
The Wall Street consensus 12-month price target for LYEL is $37.88.
